ITNM is an implantable form of posterior tibial nerve stimulation, a nerve stimulation therapy. ITNM is designed to provide consistent symptom relief with minimal disruption to daily life. The device ...

In an advance that could improve bladder cancer treatment, a novel combination of cretostimogene grenadenorepvec and pembrolizumab has shown remarkable efficacy in patients with Bacillus Calmette-Gu ...

A new survey undertaken by the Harris Poll for Johnson & Johnson has shown how standard forms of surgery and treatment for certain bladder cancer patients are causing a major long-term emotional ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved ...

But main results from sham-controlled trial still outstanding ...

“Recurrent UTIs can significantly affect quality of life,” says Gina M. Badalato, MD, a urologist and associate professor of urology at NewYork-Presbyterian/Columbia University Irving Medical Center ...

The FDA has approved an immunotherapy combination therapy for adult patients with Bacillus Calmette-Guérin-naive, high-risk ...

AstraZeneca has fired another volley in its bladder cancer competition with Merck’s Keytruda, with the FDA on Thursday ...

The FDA has approved durvalumab (Imfinzi, AstraZeneca) in combination with Bacillus Calmette-Guerin (BCG) for adults with BCG-naive, high-risk non-muscle-invasive bladder cancer (NIMBC). Approval was ...

Combination significantly improved disease-free survival in phase III trial ...

The Scottish Medicines Consortium (SMC) has accepted enfortumab vedotin (Padcev, Astellas Pharma and Pfizer) in combination with pembrolizumab for restricted use in NHS Scotland. The combination is ...

Disease-free survival improved with durvalumab plus BCG induction/maintenance versus BCG alone, reducing recurrence/progression/death risk (HR 0.68; p=0.0154) with median DFS not reached. Eligibility ...